4 / 8
Page 37
N o v e m b e r 2 3 - 2 4 , 2 0 1 8 | B a n g k o k , T h a i l a n d
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Pharma Summit 2018 & Gastro Summit 2018 Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN: 2249-622X | Volume 8
&
GLOBAL PHARMA SUMMIT
GASTROENTEROLOGY AND HEPATOLOGY
2
nd
International Conference on
Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C5-015
STEM CELL THERAPY IN END STAGE LIVER DISEASE AND LIVER FAILURE
Debashis Chowdhury
CMOSH Medical College, Bangladesh
L
iver cells have a tremendous capacity to multiply and regenerate the liver after any injury. However, this regenerative capacity
of liver cells may be overwhelmed in acute liver failure and exhausted in cirrhosis with end stage liver disease. Currently liver
transplantation is the only definitive treatment for these conditions of liver. However, due to the shortage of donor organs many
patients are dying while on waitlist for liver transplantation. As a result, it has become important to find an alternative strategy
to keep these patients alive until their own livers regenerate or donor organs become available. Regenerative medicine and stem
cell transplantation can help these patients. Adult stem cells and induced pluripotent stem cells showed good results when trans-
planted in experimental animals. Stem cells engineered from patients’ own tissue proved to be safe, as well as non-immunogenic
in clinical trials. Present review will discuss the current state of stem cell therapy, available stem cells and their application in dif-
ferent liver diseases. Keywords: Liver Failure; Cirrhosis; End Stage Liver Disease; LDLT; DDLT; Stem Cell; Regenerative Medicine;
Embryonic Stem Cell; Adult Stem Cell; Mesenchymal Stem Cell; Haematopoietic Stem Cells; iPSCs; HLCs; iHeps.